CASE STUDY: Multiplex Assays with Coregistration Enables Multiple Biomarker Analyses Across Tissue Sections

Summit Therapeutics, a life sciences company developing a therapy for Duchenne muscular dystrophy (DMD), was faced with a drug development challenge. They needed to accurately differentiate between on-going muscle regeneration and therapeutic impact of its development compound, ezutromid, in dystrophic muscle. Summit experts in DMD and utrophin modulation teamed up with Flagship experts in automated tissue biomarker qualification to deliver a solution for the evaluation of muscle biopsies in Summit’s clinical trials. In this case, multiplex assay development quantifying multiple biomarkers through coregistration, is able to clearly identify the impact of the therapeutic candidate versus regeneration.